Cryo-Cell International is a small but profitable cord blood and tissue banking franchise whose entire revenue base comes from the recurring processing and storage fees on existing client enrollments, and the Q1 FY2027 print (period ended May 31, 2026) showed the business producing a clean 7.1 percent net income margin on a flat top line. Total revenue of $7.78 million was 1.9 percent below the prior-year quarter's $7.93 million, net income of $554,586 was 55.9 percent above the prior-year quarter's $355,785, and the $0.07 diluted EPS was 75 percent above the prior-year quarter's $0.04. The combination of the $7.72 million of processing and storage fees (99.2 percent of revenue), the 55.9 percent net income growth, the 75 percent EPS growth, the -$17.8 million stockholders' deficit (a function of historical buybacks and not the current operating profile), and the $60.7 million of total assets is the cleanest single read on what the cord blood banking business model is producing. The question the next four quarters resolve is whether the company can stabilize the topline enrollment rate and continue producing margin expansion.